Identification

Name
Buserelin
Accession Number
DB06719
Type
Biotech
Groups
Approved
Biologic Classification
Protein Based Therapies
Hormones
Description

Buserelin is a synthetic peptide analog of the luteinizing hormone-releasing hormone (LHRH) agonist, which stimulates the pituitary gland's gonadotrophin-releasing hormone receptor (GnRHR). It is used in prostate cancer treatment.

Protein structure
Db06719
Protein chemical formula
C62H90N16O15
Protein average weight
Not Available
Sequences
Not Available
Synonyms
  • (Des-Gly10,D-Ser(tBu)6,Pro-NHEt9)-LHRH
  • D-Ser(Tbu)6EA10LHRH
  • Etilamide
  • Tiloryth
Product Ingredients
IngredientUNIICASInChI Key
Buserelin acetate13U86G7YSP68630-75-1PYMDEDHDQYLBRT-DRIHCAFSSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
SuprefactSolution1 mgNasalSanofi Aventis1998-02-03Not applicableCanada
SuprefactSolution1 mgSubcutaneousSanofi Aventis1998-05-05Not applicableCanada
Suprefact Depot 2 MonthsImplant6.3 mgSubcutaneousSanofi Aventis1997-02-10Not applicableCanada
Suprefact Depot 3 MonthsImplant9.45 mgSubcutaneousSanofi Aventis2000-02-24Not applicableCanada
Suprefact Inj 1mg/mlLiquid1 mgSubcutaneousHoechst Canada Inc.1988-12-311998-08-25Canada
Suprefact Intranasal Solution 1mg/mlSpray1 mgNasalHoechst Canada Inc.1988-12-311996-08-29Canada
Suprefact Liq 1mg/mlLiquid1 mgNasalHoechst Roussel Canada Inc.1993-12-312000-07-28Canada
International/Other Brands
Cinnafact (Cinnagen)
Categories
UNII
PXW8U3YXDV
CAS number
57982-77-1

Pharmacology

Indication

Buserelin may be used in the treatment of hormone-responsive cancers such as prostate cancer or breast cancer, estrogen-dependent conditions (such as endometriosis or uterine fibroids), and in assisted reproduction.

Structured Indications
Pharmacodynamics

The substitution of glycine in position 6 by D-serine, and that of glycinamide in position 10 by ethylamide, leads to a nonapeptide with a greatly enhanced LHRH effect. The effects of buserelin on FSH and LH release are 20 to 170 times greater than those of LHRH. Buserelin also has a longer duration of action than natural LHRH. Investigations in healthy adult males and females have demonstrated that the increase in plasma LH and FSH levels persist for at least 7 hours and that a return to basal values requires about 24 hours. Clinical inhibition of gonadotropin release, and subsequent reduction of serum testosterone or estradiol to castration level, was found when large pharmacologic doses (50-500 mcg SC/day or 300-1200 mcg IN/day) were administered for periods greater than 1 to 3 months. Chronic administration of such doses of buserelin results in sustained inhibition of gonadotropin production, suppression of ovarian and testicular steroidogenesis and, ultimately, reduced circulating levels of gonadotropin and gonadal steroids. These effects form the basis for buserelin use in patients with hormone-dependent metastatic carcinoma of the prostate gland as well as in patients with endometriosis.

Mechanism of action

Buserelin stimulates the pituitary gland's gonadotrophin-releasing hormone receptor (GnRHR). Buserelin desensitizes the GnRH receptor, reducing the amount of gonadotropin. In males, this results in a reduction in the synthesis and release of testosterone. In females, estrogen secretion is inhibited. While initially, there is a rise in FSH and LH levels, chronic administration of Buserelin results in a sustained suppression of these hormones.

TargetActionsOrganism
ALutropin-choriogonadotropic hormone receptorNot AvailableHuman
AGonadotropin-releasing hormone receptorNot AvailableHuman
Absorption

Buserelin is water soluble and readily absorbed after subcutaneous injection (70% bioavailable). However, bioavailability after oral absorption. When administered correctly via the nasal route, it may be absorbed in the nasal mucosa to achieve sufficient plasma levels.

Volume of distribution

Buserelin circulates in serum predominantly in intact active form. Preferred accumulation is preferentially in the liver and kidneys as well as in the anterior pituitary lobe, the biological target organ.

Protein binding

15%

Metabolism

It is metabolized and subsequently inactivated by peptidase (pyroglutamyl peptidase and chymotrypsin-like endopeptidase) in the liver and kidneys as well as in the gastrointestinal tract. In the pituitary gland, it is inactivated by membrane-located enzymes.

Route of elimination

Buserelin and its inactive metabolites are excreted via the renal and biliary routes. In man it is excreted in urine at 50% in its intact form.

Half life

The elimination half-life is approximately 50 to 80 minutes following intravenous administration, 80 minutes after subcutaneous administration and approximately 1 to 2 hours after intranasal administration.

Clearance
Not Available
Toxicity

Buserelin may induce early, transient increase in serum testosterone or estradiol which can lead in the exacerbation of signs and symptoms of metastatic prostate cancer or endometriosis. Adverse reactions reported at more than 10% occurrence include headache, loss of libido in patients with prostate cancer, hot flashes, hypermenorrhea, decreased libido in prostate cancer and endometriosis, flatulence, impotence, vaginal dryness, back pain and nasal mucosa irritation.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Buserelin.Investigational
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Buserelin.Approved, Investigational
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Buserelin.Withdrawn
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Buserelin.Experimental
AllicinThe therapeutic efficacy of Allicin can be decreased when used in combination with Buserelin.Investigational
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Buserelin.Approved
AmiodaroneBuserelin may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
AnagrelideBuserelin may increase the QTc-prolonging activities of Anagrelide.Approved
Arsenic trioxideBuserelin may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherBuserelin may increase the QTc-prolonging activities of Artemether.Approved
AsenapineBuserelin may increase the QTc-prolonging activities of Asenapine.Approved
AzithromycinBuserelin may increase the QTc-prolonging activities of Azithromycin.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Buserelin.Investigational
BedaquilineBuserelin may increase the QTc-prolonging activities of Bedaquiline.Approved
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Buserelin.Investigational
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Buserelin.Withdrawn
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Buserelin.Approved
Capromab pendetideBuserelin may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Buserelin.Experimental
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Buserelin.Experimental
CeritinibBuserelin may increase the QTc-prolonging activities of Ceritinib.Approved
ChloroquineBuserelin may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
ChlorpromazineBuserelin may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Buserelin.Approved
Choline C 11The therapeutic efficacy of Choline C 11 can be decreased when used in combination with Buserelin.Approved
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Buserelin.Experimental
CiprofloxacinBuserelin may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideBuserelin may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramBuserelin may increase the QTc-prolonging activities of Citalopram.Approved
ClarithromycinBuserelin may increase the QTc-prolonging activities of Clarithromycin.Approved
ClozapineBuserelin may increase the QTc-prolonging activities of Clozapine.Approved
Corifollitropin AlfaThe therapeutic efficacy of Corifollitropin Alfa can be increased when used in combination with Buserelin.Approved
CrizotinibBuserelin may increase the QTc-prolonging activities of Crizotinib.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Buserelin.Investigational
DisopyramideBuserelin may increase the QTc-prolonging activities of Disopyramide.Approved
DofetilideBuserelin may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronBuserelin may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidoneBuserelin may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DronedaroneBuserelin may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolBuserelin may increase the QTc-prolonging activities of Droperidol.Approved, Vet Approved
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Buserelin.Approved
EliglustatBuserelin may increase the QTc-prolonging activities of Eliglustat.Approved
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Buserelin.Approved
ErythromycinBuserelin may increase the QTc-prolonging activities of Erythromycin.Approved, Vet Approved
EscitalopramBuserelin may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Buserelin.Approved, Investigational
FlecainideBuserelin may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FluoxetineBuserelin may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolBuserelin may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
Gadobenic acidBuserelin may increase the QTc-prolonging activities of Gadobenic acid.Approved
GemifloxacinBuserelin may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Buserelin.Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Buserelin.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Buserelin.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Buserelin.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Buserelin.Approved
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Buserelin.Approved
GoserelinBuserelin may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronBuserelin may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Buserelin.Investigational
HaloperidolBuserelin may increase the QTc-prolonging activities of Haloperidol.Approved
IbutilideBuserelin may increase the QTc-prolonging activities of Ibutilide.Approved
IloperidoneBuserelin may increase the QTc-prolonging activities of Iloperidone.Approved
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Buserelin.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Buserelin.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Buserelin.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Buserelin.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Buserelin.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Buserelin.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Buserelin.Approved
LenvatinibBuserelin may increase the QTc-prolonging activities of Lenvatinib.Approved
LeuprolideBuserelin may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevofloxacinBuserelin may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Buserelin.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Buserelin.Approved
LopinavirBuserelin may increase the QTc-prolonging activities of Lopinavir.Approved
LumefantrineBuserelin may increase the QTc-prolonging activities of Lumefantrine.Approved
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Buserelin.Approved
MethadoneBuserelin may increase the QTc-prolonging activities of Methadone.Approved
MifepristoneMifepristone may increase the QTc-prolonging activities of Buserelin.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Buserelin.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Buserelin.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Buserelin.Approved, Investigational
MoxifloxacinBuserelin may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Buserelin.Approved, Investigational
NilotinibBuserelin may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
OfloxacinBuserelin may increase the QTc-prolonging activities of Ofloxacin.Approved
OndansetronBuserelin may increase the QTc-prolonging activities of Ondansetron.Approved
PaliperidoneBuserelin may increase the QTc-prolonging activities of Paliperidone.Approved
PanobinostatBuserelin may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
PazopanibBuserelin may increase the QTc-prolonging activities of Pazopanib.Approved
PentamidineBuserelin may increase the QTc-prolonging activities of Pentamidine.Approved
PerflutrenBuserelin may increase the QTc-prolonging activities of Perflutren.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Buserelin.Approved, Withdrawn
PimozideBuserelin may increase the QTc-prolonging activities of Pimozide.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Buserelin.Approved, Investigational
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Buserelin.Approved, Investigational
PrimaquineBuserelin may increase the QTc-prolonging activities of Primaquine.Approved
ProcainamideBuserelin may increase the QTc-prolonging activities of Procainamide.Approved
PromazineBuserelin may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
PropafenoneBuserelin may increase the QTc-prolonging activities of Propafenone.Approved
QuetiapineBuserelin may increase the QTc-prolonging activities of Quetiapine.Approved
QuinidineBuserelin may increase the QTc-prolonging activities of Quinidine.Approved
QuinineBuserelin may increase the QTc-prolonging activities of Quinine.Approved
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Buserelin.Approved, Investigational
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Buserelin.Approved, Investigational
SaquinavirBuserelin may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Buserelin.Approved
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Buserelin.Approved, Investigational
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Buserelin.Investigational
SotalolBuserelin may increase the QTc-prolonging activities of Sotalol.Approved
SulfisoxazoleBuserelin may increase the QTc-prolonging activities of Sulfisoxazole.Approved, Vet Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Buserelin.Approved, Investigational
TelavancinBuserelin may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinBuserelin may increase the QTc-prolonging activities of Telithromycin.Approved
TetrabenazineBuserelin may increase the QTc-prolonging activities of Tetrabenazine.Approved
ThioridazineBuserelin may increase the QTc-prolonging activities of Thioridazine.Withdrawn
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Buserelin.Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Buserelin.Approved
ToremifeneBuserelin may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Buserelin.Withdrawn
VandetanibBuserelin may increase the QTc-prolonging activities of Vandetanib.Approved
VemurafenibBuserelin may increase the QTc-prolonging activities of Vemurafenib.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Buserelin.Approved, Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Buserelin.Approved, Investigational
ZiprasidoneBuserelin may increase the QTc-prolonging activities of Ziprasidone.Approved
ZuclopenthixolBuserelin may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Link [Link]
External Links
KEGG Drug
D01831
PubChem Substance
347910362
ChEMBL
CHEMBL1909304
Wikipedia
Buserelin
ATC Codes
L02AE01 — Buserelin
AHFS Codes
  • 10:00.00 — Antineoplastic Agents
  • 92:00.00 — Miscellaneous Therapeutic Agents

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentProstate Cancer1
1TerminatedTreatmentNon Castrate Metastatic Prostate Cancer1
1, 2CompletedTreatmentOvarian Stimulation1
1, 2Unknown StatusTreatmentAssisted Reproductive Technology therapy1
3Active Not RecruitingTreatmentProstate Cancer2
3CompletedSupportive CareBone destruction / Prostate Cancer1
3CompletedTreatmentProstate Cancer2
3SuspendedTreatmentInfertilities1
3TerminatedTreatmentProstate Cancer1
3Unknown StatusScreeningEmbryo's Genetic and Chromosomal Quality1
3Unknown StatusTreatmentInfertilities1
3Unknown StatusTreatmentProstate Cancer1
4CompletedTreatmentInfertilities1
4CompletedTreatmentOHSS (Ovarian Hyperstimulation)1
4CompletedTreatmentOvarian Stimulation1
4CompletedTreatmentPregnancy1
4RecruitingTreatmentInfertilities1
4TerminatedTreatmentAssisted Reproductive Technology therapy / Ovarian Stimulation1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
SolutionNasal1 mg
SolutionSubcutaneous1 mg
ImplantSubcutaneous6.3 mg
ImplantSubcutaneous9.45 mg
LiquidSubcutaneous1 mg
SprayNasal1 mg
LiquidNasal1 mg
Prices
Not Available
Patents
Not Available

Properties

State
Liquid
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
General Function
Luteinizing hormone receptor activity
Specific Function
Receptor for lutropin-choriogonadotropic hormone. The activity of this receptor is mediated by G proteins which activate adenylate cyclase.
Gene Name
LHCGR
Uniprot ID
P22888
Uniprot Name
Lutropin-choriogonadotropic hormone receptor
Molecular Weight
78642.01 Da
References
  1. Kirby RS, Fitzpatrick JM, Clarke N: Abarelix and other gonadotrophin-releasing hormone antagonists in prostate cancer. BJU Int. 2009 Dec;104(11):1580-4. doi: 10.1111/j.1464-410X.2009.08924.x. [PubMed:20053189]
Kind
Protein
Organism
Human
Pharmacological action
Yes
General Function
Peptide binding
Specific Function
Receptor for gonadotropin releasing hormone (GnRH) that mediates the action of GnRH to stimulate the secretion of the gonadotropic hormones luteinizing hormone (LH) and follicle-stimulating hormone...
Gene Name
GNRHR
Uniprot ID
P30968
Uniprot Name
Gonadotropin-releasing hormone receptor
Molecular Weight
37730.355 Da
References
  1. Kirby RS, Fitzpatrick JM, Clarke N: Abarelix and other gonadotrophin-releasing hormone antagonists in prostate cancer. BJU Int. 2009 Dec;104(11):1580-4. doi: 10.1111/j.1464-410X.2009.08924.x. [PubMed:20053189]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Oxygen binding
Specific Function
Catalyzes the formation of aromatic C18 estrogens from C19 androgens.
Gene Name
CYP19A1
Uniprot ID
P11511
Uniprot Name
Aromatase
Molecular Weight
57882.48 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 07, 2010 16:44 / Updated on November 13, 2017 21:49